Two novel autoantibodies, anti-Sp4 and anti-CCAR1, have recently been described which co-occur with anti-TIF1γ and significantly attenuate the cancer risk to a level comparable to that of the general population [23, 37, 38]. The gene discussed is SP4; the disease is cancer.